Notice Pursuant to the National Cooperative Research and Production Act of 1993-Alliance for OpenUSD Series LLC, 52095 [2024-13636]
Download as PDF
<![CDATA[
Federal Register / Vol. 89, No. 120 / Friday, June 21, 2024 / Notices
of Justice published a notice in the
Federal Register pursuant to section
6(b) of the Act on July 17, 2015 (80 FR
42537).
The last notification was filed with
the Department on January 25, 2024. A
notice was published in the Federal
Register pursuant to section 6(b) of the
Act on April 16, 2024 (89 FR 26926).
DEPARTMENT OF JUSTICE
Antitrust Division
Notice Pursuant to the National
Cooperative Research and Production
Act of 1993—Alliance for OpenUSD
Series LLC
ddrumheller on DSK120RN23PROD with NOTICES1
BILLING CODE P
Notice Pursuant to the National
Cooperative Research and Production
Act of 1993—Rapid Response
Partnership Vehicle
BILLING CODE 4410–11–P
Notice is hereby given that, on April
25, 2024, pursuant to section 6(a) of the
National Cooperative Research and
Production Act of 1993, 15 U.S.C. 4301
et seq. (‘‘the Act’’), Alliance for
OpenUSD Series LLC (‘‘AOUSD’’) has
filed written notifications
simultaneously with the Attorney
General and the Federal Trade
Commission disclosing additions or
changes to its standards development
activities. The notifications were filed
for the purpose of extending the Act’s
provisions limiting the recovery of
antitrust plaintiffs to actual damages
under specified circumstances.
Specifically, AOUSD has formed two
additional Working Groups (‘‘WGs’’) in
March 2024: a Materials WG and a
Geometry WG. The Materials WG will
standardize the description of materials
in OpenUSD. Its initial focus and first
deliverable will be the USD Material
Interchange Specification, which will
comprise a set of patterns and BSDF
nodes comprising the MaterialX
standard libraries. The Geometry WG
will define and evolve the strategy for
the description of 3D geometry in
OpenUSD. Its first deliverable will be
the USD Transformable 3D Geometry
Specification that will describe the
surfaces and volume representations,
spatial transformations, rules of
determining primary visibility, and
other properties required for imaging
those representations.
On October 30, 2023, AOUSD filed its
original notification pursuant to section
6(a) of the Act. The Department of
Justice published a notice in the Federal
Register pursuant to section 6(b) of the
Jkt 262001
[FR Doc. 2024–13636 Filed 6–20–24; 8:45 am]
Antitrust Division
[FR Doc. 2024–13659 Filed 6–20–24; 8:45 am]
17:46 Jun 20, 2024
Suzanne Morris,
Deputy Director, Civil Enforcement
Operations, Antitrust Division.
DEPARTMENT OF JUSTICE
Suzanne Morris,
Deputy Director Civil Enforcement
Operations, Antitrust Division.
VerDate Sep<11>2014
Act on December 15, 2023 (88 FR
86939).
Notice is hereby given that, on April
12, 2024, pursuant to section 6(a) of the
National Cooperative Research and
Production Act of 1993, 15 U.S.C. 4301
et seq. (‘‘the Act’’), Rapid Response
Partnership Vehicle (‘‘RRPV’’) has filed
written notifications simultaneously
with the Attorney General and the
Federal Trade Commission disclosing
changes in its membership. The
notifications were filed for the purpose
of extending the Act’s provisions
limiting the recovery of antitrust
plaintiffs to actual damages under
specified circumstances.
Specifically, A-line, Inc., Signal Hill,
CA; ANP Technologies, Inc., Newark,
DE; ARNAV Biotech Corp., Atlanta, GA;
Action Medical Technologies LLC,
Conshohocken, PA; AmerStem, Inc.,
Camarillo, CA; American Type Culture
Collection, Manassas, VA; Aposense,
Ltd., Petach Tikva, ISRAEL; Appili
Therapeutics USA, Inc., Frederick, MD;
Aptitude Medical Systems, Goleta, CA;
Arranta Bio MA LLC, Watertown, MA;
Asha Therapeutics LLC, Tampa, FL;
BDO Public Sector LLC, Mclean, VA;
BRCR Medical Center, Inc., Plantation,
FL; Battelle Memorial Institute,
Columbus, OH; BioInfoExperts LLC,
Thibodaux, LA; Boost Biopharma, Inc.,
Amherst, MA; Bracane Company, Plano,
TX; Capra Biosciences, Inc., Manassas,
VA; Capricor Therapeutics, Inc., San
Diego, CA; CellCarta Biosciences, Inc.,
Montreal, CANADA; Cerba Research
USA, Inc., Lake Success, NY;
Clarametyx Biosciences, Inc., Columbus,
OH; Clarus Biologics, Inc., Chapel Hill,
NC; Cue Health, Inc., San Diego, CA;
D’Angelo Technologies LLC,
Beavercreek, OH; DEKA Research &
Development Corp., Manchester, NH;
Datavant, Phoenix, AZ; Deutsches
Zentrum für Infektionsforschung e.V.,
Braunschweig, GERMANY; Diagnostic
Consulting Network LLC dba DCN
Diagnostics, Carlsbad, CA; Diasorin
Molecular, Cypress, CA; EMD Millipore
dba MilliporeSigma, Burlington, MA;
PO 00000
Frm 00086
Fmt 4703
Sfmt 4703
52095
Ethris GmbH, Planegg, GERMANY;
FONDAZIONE BIOTECNOPOLO DI
SIENA, SIENA, ITALY; Flagship Labs,
Cambridge, MA; Fred Hutchinson
Cancer Center, Seattle, WA; Genentech,
South San Francisco, CA; GiwoTech,
Inc., Wilmington, DE; Global Action
Alliance, Inc., Ashburn, VA; HDT Bio
Corp., Seattle, WA; Hope Biosciences,
Sugar Land, TX; IQVIA Government
Solutions, Inc., Falls Church, VA; Icahn
School of Medicine at Mount Sinai,
New York, NY; InBios International,
Seattle, WA; Injection Safety Industries
LLC, Bowling Green, KY; Inovio
Pharmaceuticals, Plymouth Meeting,
PA; Integrated Biotherapeutics LLC dba
IBT Bioservices, Rockville, MD; LTS
Lohmann Therapie-Systeme AG,
Andernach, GERMANY; Labcorp,
Burlington, NC; Labcorp-Monogram
Biosciences, South San Francisco, CA;
Lyndra Therapeutics, Inc., Watertown,
MA; Major, Inc., Los Angeles, CA;
MalarVx, Inc., Seattle, WA; Mirimus,
Inc., Brooklyn, NY; Nature’s Toolbox,
Inc., Rio Rancho, NM; New Horizon
Biotech, Inc., Nazareth, PA; OncoC4,
Inc., Rockville, MD; PIF Partners LLC,
Englewood, NJ; PharmaJet, Inc., Golden,
CO; Precision for Medicine, Inc.,
Frederick, MD; Revvity Health Sciences,
Hopkinton, MA; Rocketvax, Ltd., Basel,
SWITZERLAND; Selva Therapeutics,
Inc., San Mateo, CA; Sentio BioSciences
LLC, Maryland Heights, MO; Solaris
Vaccines, Inc., Fort Collins, CO; Spring
Discovery, Inc., San Carlos, CA;
Technical Resources International, Inc.,
Bethesda, MD; The Emmes Company
LLC, Rockville, MD; The Pandemic
Institute (Legally hosted by the
University of Liverpool), Liverpool,
UNITED KINGDOM; Tonix
Pharmaceutical Holdings, Chatham, NJ;
Trawsfynydd Therapeutics, Inc.,
Rockville, MD; US Specialty
Formulations LLC, Allentown, PA;
Univercells S.A., Brussels, BELGIUM;
VaxForm LLC, Bethlehem, PA;
VisMederi Srl, Siena, ITALY; Vyriad,
Inc., Rochester, MN; Walgreen Co.,
Deerfield, IL; Yourbio Health, Medford,
MA; and iosBio, Ltd., Haywards Heath,
UNITED KINGDOM, have been added as
parties to this venture.
No other changes have been made in
either the membership or planned
activity of the group research project.
Membership in this group research
project remains open, and RRPV intends
to file additional written notifications
disclosing all changes in membership.
On January 5, 2024, RRPV filed its
original notification pursuant to section
6(a) of the Act. The Department of
Justice published a notice in the Federal
E:\FR\FM\21JNN1.SGM
21JNN1
]]>Agencies
[Federal Register Volume 89, Number 120 (Friday, June 21, 2024)]
[Notices]
[Page 52095]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-13636]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Antitrust Division
Notice Pursuant to the National Cooperative Research and
Production Act of 1993--Alliance for OpenUSD Series LLC
Notice is hereby given that, on April 25, 2024, pursuant to section
6(a) of the National Cooperative Research and Production Act of 1993,
15 U.S.C. 4301 et seq. (``the Act''), Alliance for OpenUSD Series LLC
(``AOUSD'') has filed written notifications simultaneously with the
Attorney General and the Federal Trade Commission disclosing additions
or changes to its standards development activities. The notifications
were filed for the purpose of extending the Act's provisions limiting
the recovery of antitrust plaintiffs to actual damages under specified
circumstances. Specifically, AOUSD has formed two additional Working
Groups (``WGs'') in March 2024: a Materials WG and a Geometry WG. The
Materials WG will standardize the description of materials in OpenUSD.
Its initial focus and first deliverable will be the USD Material
Interchange Specification, which will comprise a set of patterns and
BSDF nodes comprising the MaterialX standard libraries. The Geometry WG
will define and evolve the strategy for the description of 3D geometry
in OpenUSD. Its first deliverable will be the USD Transformable 3D
Geometry Specification that will describe the surfaces and volume
representations, spatial transformations, rules of determining primary
visibility, and other properties required for imaging those
representations.
On October 30, 2023, AOUSD filed its original notification pursuant
to section 6(a) of the Act. The Department of Justice published a
notice in the Federal Register pursuant to section 6(b) of the Act on
December 15, 2023 (88 FR 86939).
Suzanne Morris,
Deputy Director, Civil Enforcement Operations, Antitrust Division.
[FR Doc. 2024-13636 Filed 6-20-24; 8:45 am]
BILLING CODE P
